
CATalyst Council Unveils 2025 Feline Market Insights Report Volume II: $12 Billion Market Reveals $20 Billion Opportunity to Close the Feline Care Gap
"CATalyst Council is a 501(c)(3) nonprofit coalition of leaders in veterinary medicine, animal welfare, and the pet industry. It drives innovation in feline care by analyzing U.S. feline healthcare dynamics, owner behaviors, and veterinary trends."
The report confirms that, while the canine segment has dominated revenue in size, feline practice revenue has had higher average annual growth over the past 5 years. Beyond that, the current US total addressable feline veterinary market (TAM) remains at more than 2.5 times its current size, or an incremental $20 billion growth opportunity. This feline TAM simply assumes that cats reach the same rate of medicalization and level of care per visit as dogs presently enjoy.
' The growth we see in feline visits today, combined with favorable pet age demographics and an ongoing recovery in US real per capita income points to an exceptional growth opportunity arising in today's pet healthcare market,' said Jon Ayers, CATalyst Council board member and chair of its Market Insights Committee.
'Understanding feline species-specific stress responses and caregiver mindsets is critical,' said Kristin Wuhrman, Vice Chair of the CATalyst Council. 'By addressing costs, perceptions of value, and visit-related anxiety, adopting FelineVMA's Cat Friendly Practice care protocols, and educating caregivers on cat behavior, we can overcome key barriers and deepen the bond between cats, caregivers, and clinics, ultimately ensuring more cats receive the care they need.'
Volume II delivers the strategic playbook that practices, consolidators, industry suppliers, and investors need to build their investment plans:
Key Findings
$12 Billion Feline Veterinary Market with approximately 9% average annual growth: In 2024, feline practice revenue reached an estimated $11.7 billion, up from $7.6 billion in 2019, outpacing canine average annual growth (estimated at 7.5%, with 2024 US canine veterinary market of $48 billion).
Unmet Medicalization Gap: Only an estimated 30% of U.S. household-owned cats received a visit to a veterinary practice in 2024, compared to a corresponding estimated 65–70% for dogs.
Practice-Level Revenue Opportunity: Closing the care gap to match canine medicalization could expand the addressable market from $12 billion to $32 billion, adding an average of $680,000 (approximately 33%) to annual revenue to the average two-million-dollar U.S. veterinary practice location.
'Addressing the feline care gap should be a call to action for the entire animal health community,' adds Anne Ward, Chair of CATalyst Council. 'The feline veterinary segment has come of age with the opportunity for greater species-specific innovation by the industry and care profession.'
Recovery Forecast: CATalyst projects that pet age demographic headwinds faced in the last three years as a result of the aging and mortality of pets adopted during the depressed years of 2009-2011 following the 2008 great financial crisis, could turn to tailwinds as pets adopted from 2013 onwards reach their geriatric years, beginning in late 2025 or 2026. As the median lifespan of a cat is a little over 14 years, and correspondingly 13 years for a dog, these last few years of pet age are when visits are the highest after the first year of life. 'Pet demographics are hard trends and as inevitable as pet mortality and practice taxes,' said Jane Brunt DVM, proactive feline practice owner and CATalyst Council Executive Director.
This tailwind, combined with the potential for continued consumer inflation-adjusted income recovery, would accelerate feline visit growth and help reverse canine visit declines, starting in the next 6 to 18 months.
Looking Ahead: Data-Driven Validation
Building on these insights, CATalyst Council plans to field a 30,000 US-household 'State of the Cat' survey in late 2025. This extensive, statistically robust study will drill into regional, demographic, and behavioral nuances, enabling early adopters to pilot hyper-targeted programs and measure ROI against validated owner and feline needs. The 2025 CATalyst Feline Market Insights Reports, released quarterly and available exclusively to CATalyst Council sponsors, will inform each phase. CATalyst plans to share high-level conclusions throughout the year via press releases and LinkedIn, ensuring veterinary professionals, industry stakeholders, and decision-makers receive evidence-based updates.
To receive updates or inquire about the benefits of sponsorship, please visit catalystcouncil.org, and follow Catalyst Council on LinkedIn.
CATalyst Council is a national organization dedicated to accelerating innovation in feline care and enhancing quality of life for cats and their people. CATalyst's vision is to ensure all companion cats receive lifelong care by using evidence-based resources, embracing community-wide relationships for optimal health outcomes, and celebrating the human-feline bond.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
a minute ago
- Business Wire
āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2
BURLINGAME, Calif.--(BUSINESS WIRE)-- āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced an exclusive licensing agreement with Mereo BioPharma (NASDAQ: MREO) for vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2), a rare, debilitating bone disorder with no approved therapies. The licensing of vantictumab represents a strategic expansion of āshibio's pipeline of clinical-stage assets that address high unmet needs and carry significant clinical and commercial potential. ADO2, also known as Albers-Schönberg disease, is a genetic disorder caused by reduced function of osteoclasts. Impaired osteoclast function results in dense, brittle bone and leads to complications such as multiple fractures, poor bone healing, low blood counts (due to bone marrow sequestration), and painful nerve compression. The most common form of osteopetrosis, ADO2 results from a mutation in the chloride channel 7 (CLCN7) gene and has a reported incidence of 1 in 20,000 births. 1 'People living with autosomal dominant osteopetrosis type 2 face a lifetime of bone-related complications resulting in significant morbidity, multiple surgical procedures, chronic pain, and impaired quality of life – yet patients have no approved therapy to address the disease,' said āshibio Chief Executive Officer Pankaj Bhargava, MD. 'Bringing vantictumab into our pipeline reflects our commitment to advancing therapies for rare skeletal conditions and improving the lives of those affected by serious bone disorders.' Vantictumab is a monoclonal antibody that selectively binds to certain frizzled (Fzd) receptors and inhibits Wnt signaling pathways. 2 Originally intended for the treatment of cancer, vantictumab has been previously evaluated in oncology clinical trials, demonstrating a favorable safety and pharmacokinetic profile. Previous clinical trials have provided biomarker data that directly support the activity of vantictumab on osteoclast function. These data significantly derisk the clinical program and allow āshibio to rapidly advance vantictumab into clinical development for ADO2. Preclinical data supporting the development of vantictumab in ADO2 will be presented at the upcoming American Society for Bone and Mineral Research (ASBMR) annual meeting, which takes place September 5-8, 2025 in Seattle, Wash. Under the terms of the agreement, āshibio will lead global clinical development for vantictumab in adult and pediatric patients. Mereo has granted āshibio an exclusive license to develop and commercialize vantictumab in the US and the rest of the world, excluding Europe, where Mereo retains commercial rights. About āshibio āshibio is a privately held, clinical-stage biotechnology company developing a pipeline of novel therapeutics for the treatment of bone disorders. Founded in 2022, āshibio exited stealth mode in June 2024 with $40 million in seed and Series A financing. The company has initiated a Phase 2/3 trial of its lead asset, andecaliximab, in patients with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by progressive heterotopic ossification (HO), a pathological condition characterized by abnormal bone formation in muscle and soft tissues. āshibio has also initiated a development program in non-hereditary heterotopic ossification (NHHO), a severely disabling condition for which there are no approved therapies. The first study in the NHHO program is a Phase 1b trial of andecaliximab in patients with spinal cord injury at risk of HO. For more information, visit About Mereo BioPharma Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); and alvelestat for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo's partner, Ultragenyx Pharmaceutical, Inc., has completed enrollment in the Phase 3 portion of a pivotal Phase 2/3 study in pediatric patients and young adults (5 to 25 years old) for setrusumab in OI and in the Phase 3 study in pediatric patients (2 to <7 years old). The partnership with Ultragenyx includes potential additional milestone payments of up to $245 million and royalties to Mereo on commercial sales in Ultragenyx territories. Mereo has retained EU and UK commercial rights and will pay Ultragenyx royalties on commercial sales in those territories. Setrusumab has received Orphan Designation for osteogenesis imperfecta from the European Commission ('EC') and the U.S. Food and Drug Administration (FDA), PRIME designation from the European Medicines Agency (EMA), and Breakthrough Therapy and Rare Pediatric Disease Designations from the FDA. Alvelestat has received Orphan Designation for AATD from the EC and the FDA, and Fast Track designation from the FDA for AATD-LD. Mereo has also entered into an exclusive global license agreement with ReproNovo SA, a reproductive medicine company, for the development and commercialization of leflutrozole, a non-steroidal aromatase inhibitor. In addition to the rare disease programs, Mereo has two oncology product candidates, etigilimab, an anti-TIGIT; and navicixizumab for the potential treatment of late-line ovarian cancer. Navicixizumab has been partnered with Feng Biosciences, Inc. in a global licensing agreement that includes milestone payments and royalties. For more information, visit 1 Wu CC, Econs MJ, DiMeglio LA, et al. Diagnosis and management of osteopetrosis: consensus guidelines from the Osteopetrosis Working Group. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3111-3123. doi: 10.1210/jc.2017-01127 2 Diamond JR, Becerra C, Richards D, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat 10.1007/s10549-020-05817-w


Business Wire
a minute ago
- Business Wire
ImmunityBio Announces Phase 2 Study of ANKTIVA ® in Patients with Long COVID
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA ® (nogapendekin alfa inbakicept-pmln), in patients with long COVID. An estimated one in five Americans with a previous COVID-19 infection has long COVID, which is comprised of a broad range of symptoms that can substantially impact a patient's quality of life. Long COVID remains a significant public health challenge with no currently available established therapies. The new study, called COVID-4.019-Long, further expands the company's clinical research efforts to assess ANKTIVA's potential beyond cancer or cancer-related diseases. Currently, ANKTIVA is being evaluated alone and with other agents in multiple studies for different forms of bladder cancer, non-small cell lung cancer, glioblastoma, non-Hodgkin lymphoma, Lynch syndrome, ovarian cancer and Human Papillomavirus (HPV) associated tumors. ANKTIVA is also being studied in Human Immunodeficiency Virus (HIV) and lymphopenia. The primary objective of the exploratory, single-arm study (NCT0712372 7) is to evaluate the safety of ANKTIVA, injected under the skin (subcutaneously), in participants with long COVID. The secondary objective is to assess the effect of ANKTIVA on absolute lymphocyte count. Exploratory objectives include evaluation of ANKTIVA's ability to improve post-COVID natural killer (NK) cell and CD8+ T cell counts, and assessment of the immunological function of NK cells and CD8+ T cells. 'We are excited to study ANKTIVA for the treatment of long COVID, a substantial public health concern,' said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. 'Early in the pandemic, the common assumption was SARS-CoV-2 would prove to be a transient infection, as is the case with coronaviruses in general. But we now know viral nucleic acid and proteins can be in the gut mucosa months after infection. As such, an antiviral strategy looks insufficient to treat or cure long COVID. Based on clinical insights to date, we believe ANKTIVA may be a new therapeutic option for this chronic and potentially disabling condition by enhancing immune function, facilitating viral clearance, and addressing underlying contributions to long COVID.' The study, which is being conducted by ImmunityBio and aims to recruit up to 40 participants who meet the long COVID criteria, as established by the World Health Organization (WHO), is now accepting patients for initial screening to determine study eligibility. The safety and tolerability of ANKTIVA for long COVID is also being assessed in a separate Phase 2 study conducted at the University of California – San Francisco. Both studies are supported by ImmunityBio. To learn more, visit ANKTIVA is currently approved by the U.S. Food and Drug Administration with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. About Long COVID Long COVID is a serious illness that can cause chronic health conditions requiring comprehensive care. It may also lead to disability. 2 Long COVID impacts approximately 1 in 5 Americans adults who had a previous COVID-19 infection. 1 It can include a wide range of ongoing symptoms and conditions that can last weeks, months, or even years after COVID-19 illness. 1 Some of the common among the more than 200 identified symptoms include fatigue, brain fog, coughing, shortness of breath, heart palpitations and change in smell or taste. 3 Anyone who had a SARS-CoV-2 infection, the virus that causes COVID-19, can experience Long COVID, including children. 1 Long COVID remains a significant public health challenge with no currently available established treatments. About ANKTIVA ® (nogapendekin alfa inbakicept-pmln) The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA® overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. A key component in the company's BioShield platform, ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA® mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. IMPORTANT SAFETY INFORMATION INDICATION AND USAGE: ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA® with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Please see the complete Prescribing Information for ANKTIVA ® at References: Robertson MM, Qasmieh SA, Kulkarni SG, et al. The Epidemiology of Long Coronavirus Disease in US Adults. Clin Infect Dis. May 3 2023;76(9):1636-1645. U.S. Centers for Disease Control and Prevention. Long COVID Basics. July 2025. Available at U.S. Centers for Disease Control and Prevention. Long COVID Signs and Symptoms. July 2025. Available at About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding potential implications to be drawn from preliminary clinical study results, clinical trial enrollment, timing, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's CancerBioShield™ platform, the potential health conditions associated with Long COVID, potential patient populations and implications thereof, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that have the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'goal,' 'could,' 'estimates,' 'scheduled,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'predicts,' 'indicate,' 'projects,' 'is,' 'seeks,' 'should,' 'will,' 'strategy,' and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding participation and enrollment and potential results from the clinical trial described herein, (ii) whether clinical trials will result in registrational pathways, (iii) whether clinical trial data will be accepted by regulatory agencies, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vi) potential delays in product availability and regulatory approvals, (vii) ImmunityBio's ability to retain and hire key personnel, (viii) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (ix) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (x) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xi) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading 'Risk Factors' in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on August 5, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.


Business Wire
31 minutes ago
- Business Wire
Butterfly Network Joins Research Project Studying the Impact of AI-Assisted POCUS on Early Tuberculosis Detection in Sub-Saharan Africa
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)-- Butterfly Network, Inc. ('Butterfly', 'the Company') (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound, today announced its role in the international research study CAD LUS4TB that will evaluate the impact of AI-assisted point-of-care ultrasound (POCUS) on tuberculosis (TB) triage in under-resourced settings. For patients in regions such as Sub-Saharan Africa (SSA) with no access to ultrasound in primary care, there is a critical need for accessible diagnostic tools. WHO data suggests that 2.5 million people fell ill with TB in Africa in 2022, accounting for a quarter of new TB cases worldwide, and over 33% of TB deaths occurred in the African region. Butterfly is part of the CAD LUS4TB consortium alongside 10 research institutions in Africa and Europe. The consortium is trialing a new AI algorithm, using Butterfly's software development platform. The program automates image classification for TB from images obtained using Butterfly's portable ultrasound devices. AI-aided POCUS will be used to help frontline healthcare workers quickly and more accurately detect TB at point of care in an initial trial in the SSA region. The European Union's Global Health EDCTP3 Joint Undertakings has provided €10 million in funding for this work. The trial initiates in September and will involve 3,000 adult patients across SSA. Patients will be treated by non-radiologist healthcare workers supported by AI-led POCUS to identify likely TB indicators. This approach empowers healthcare workers to assess patients for TB without needing extensive ultrasound training or access to lab testing. 'Butterfly is proud to continue improving global health equity through our role in this project. Patients in lower-resource settings need easier access to diagnostic imaging to detect and treat deadly diseases such as TB before it claims more lives,' said Dr. Sachita Shah, VP of Global Health, Butterfly Network. 'We believe that this study has the capacity to demonstrate that faster, safer, more accessible triage with AI-enabled POCUS can drastically reduce morbidity and mortality from TB and other lung diseases in low- and middle-income countries.' The CAD LUS4TB initiative also seeks to generate an evidence-driven policy that supports AI-aided lung ultrasound in TB management, with the long-term goal of the technology's incorporation into national healthcare policies and systems. Powered by the company's Ultrasound-on-Chip™ technology, Butterfly delivers sharp image quality and powerful AI capabilities in a single handheld probe. Butterfly's portable hardware, coupled with the company's partner platform for software development, uniquely positions Butterfly POCUS as a suitable vehicle for deploying new, innovative AI algorithms to diagnose leading causes of global mortality, including TB. The study is the latest innovation in Butterfly's ongoing commitment to improving access to ultrasound for healthcare professionals and patients globally, particularly in underserved areas. Butterfly previously supported the TrUST study, an international prospective trial which developed AI algorithms for diagnosis of TB using Butterfly. Butterfly's Global Health Program works with hundreds of non-profit and humanitarian organizations in over 115 countries to provide sustainable and equitable digital health solutions to the world's most vulnerable populations. About Butterfly Network Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world's first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore's Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly's innovations have also been recognized by Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements. Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about Butterfly's Global Health Program, please visit: